-
Mashup Score: 52
Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy alone in cisplatin-eligible adults with unresectable or metastatic urothelial carcinoma If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU A decision on the EU marketing authorization is expected by June 2024 Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation. The final EC
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 93Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC by The Uromigos - 1 month(s) ago
Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.
Source: podcasters.spotify.comCategories: General Medicine News, Hem/OncsTweet-
Easter paper of the month with @MattGalsky - gem/cis/nivo with bladder sparing approaches and single agent nivo in responders. Magic data. Move to a cystectomy free era I hope . @NatureMedicine https://t.co/ZMCqsegjen
-
-
Mashup Score: 393ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma - 2 month(s) ago
The following ESMO Clinical Practice Guideline (CPG) has been recently updated with new treatment recommendations and an updated algorithm for managing treatment-naive advanced or metastatic urothelial carcinoma (stage IV): Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.1
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
New @myESMO guidlines for advanced bladder cancer @Annals_Oncology. Enforumab Vedotin & pembro is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant. Gem/cis/nivo or maintenance avelumab for pts where EVP not available https://t.co/wx2AD4eEGn https://t.co/acDNKSPHzp
-
-
Mashup Score: 332ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma - 2 month(s) ago
The following ESMO Clinical Practice Guideline (CPG) has been recently updated with new treatment recommendations and an updated algorithm for managing treatment-naive advanced or metastatic urothelial carcinoma (stage IV): Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.1
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
New @myESMO guidlines for advanced bladder cancer @Annals_Oncology. Enforumab Vedotin & pembro is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant. Gem/cis/nivo or maintenance avelumab for pts where EVP not available https://t.co/wx2AD4eEGn https://t.co/acDNKSPHzp
-
-
Mashup Score: 155
Quick Take Video Summary from The New England Journal of Medicine — Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Cancer
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
A short and effective video summarising the EV302 study in 1st line advanced bladder cancer. It shows enfortumab vedotin significantly outperforming standard chemotherapy and changing the standard of care in this lethal disease @NEJM https://t.co/ofUwjCZOjP
-
-
Mashup Score: 2ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer by The Uromigos - 3 month(s) ago
Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.
Source: podcasters.spotify.comCategories: General Medicine News, Hem/OncsTweet-
HPN328 is a tri-specific T cell engager @mishabeltran https://t.co/9PSGn87h5f
-
-
Mashup Score: 36ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer by The Uromigos - 3 month(s) ago
Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.
Source: podcasters.spotify.comCategories: General Medicine News, UrologyTweet-
Have a quick listen to our podcast with @neerajaiims on cabo + atezo in CRPC. https://t.co/CaEWKgsBHm
-
-
Mashup Score: 36ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer by The Uromigos - 3 month(s) ago
Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.
Source: podcasters.spotify.comCategories: General Medicine News, UrologyTweet-
Have a quick listen to our podcast with @neerajaiims on cabo + atezo in CRPC. https://t.co/CaEWKgsBHm
-
-
Mashup Score: 30Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer by The Uromigos - 5 month(s) ago
Rahul Aggarwal describes his phase 1/2 study with only 1 cycle of Lu-177 in CRPC.
Source: podcasters.spotify.comCategories: General Medicine News, UrologyTweet-
Rahul Aggarwal describes his phase 1/2 study with only 1 cycle of Lu-177 with pembro in CRPC. A discussion about Prince’s greatest hits ensues. https://t.co/UDajnV4Q6J
-
-
Mashup Score: 9The cancer-immunity cycle: Indication, genotype, and immunotype - 7 month(s) ago
The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterat…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Updated cancer immunity cycle published. A subcycle has been introduced to emphasise the key role for the TME, particularly DCs and TLSs, in sustaining the anti-tumor T cell response. Immune phenotypes now feature @TurleyLabGNE @DanChenMDPhD & Ira Mellman https://t.co/8fcjdMRYHv https://t.co/SOY6Yh7ShF
-
A +ve CHMP opinion for gem/cis + nivolumab (CheckMate -901 trial) today @MichvdHeijden @MattGalsky #APCCC24 Likely to result in EMA approval. This will compete with maintenance avelumab due to ⬆️ RR & CR rate, but EV/pembro will follow soon I hope . https://t.co/XMqVGly80l